View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
November 8, 2021updated 11 Jul 2022 2:19pm

Calithera to suspend Phase II NSCLC trial due to lack of clinical benefit

The company estimates to save between $10m and $15m with the trial suspension.

Calithera Biosciences has reported that it will suspend the Phase II KEAPSAKE clinical trial of telaglenastat in stage IV non-squamous non-small cell lung cancer (NSCLC) due to a lack of clinical benefit.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

This placebo-controlled, randomised, double-blind trial analysed the safety and anti-tumour activity of telaglenastat in combination with standard-of-care chemoimmunotherapy as front-line treatment for stage IV NSCLC patients.

These subjects had tumours with Kelch Like ECH Associated Protein 1 (KEAP1) or Nuclear factor-erythroid factor 2-related factor 2 (NRF2) mutations.

The trial had randomised a total of 40 subjects when it was unblinded on 27 October 2021.

The efficacy results, which included investigator-evaluated progression-free survival, did not show any clinical benefit.

Interim analysis findings of the trial also showed a reduced likelihood of an eventual positive outcome.

No change in the safety profile between the two trial groups was observed.

Calithera voluntarily terminated the trial on obtaining approval from the KEAPSAKE Steering Committee members and have informed the US Food and Drug Administration of the latest development.

It estimates to save between $10m and $15m with the trial suspension.

With no current plans to advance the development of telaglenastat, the firm will now prioritise developing recently acquired targeted oncology therapies, notably sapanisertib and mivavotinib.

Calithera CEO Susan Molineaux said: “Our near-term clinical development plans include leveraging our clinical and biomarker expertise in the KEAP1/NRF2 pathway in the development of our mTORC1/2 inhibitor sapanisertib in squamous non-small cell lung cancer, as well as advancing the development of our SYK inhibitor mivavotinib in specific biomarker-defined populations of diffuse large B-cell lymphoma.

“In addition, we are continuing the development of our arginase inhibitor CB-280 for the treatment of cystic fibrosis.”

In July 2019, Calithera started a Phase I/II trial of telaglenastat plus Pfizer ’s palbociclib (Ibrance) to treat cancer.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena